双重血浆分子吸附系统治疗过程中肝素抗凝效果的影响因素研究

doi:10.3969/j.issn.1006-7795.2021.04.022

首都医科大学学报 ›› 2021, Vol. 42 ›› Issue (4): 647-652.doi: 10.3969/j.issn.1006-7795.2021.04.022

双重血浆分子吸附系统治疗过程中肝素抗凝效果的影响因素研究

孔明¹, 李爽², 耿华^1,3, 周莉¹, 徐曼曼¹, 刘静², 陈煜^1*

1.首都医科大学附属北京佑安医院肝病中心四科, 北京 100069;
2.首都医科大学附属北京佑安医院血液净化中心, 北京 100069;
3.河北中石油中心医院感染科, 河北廊坊 065000

收稿日期:2021-05-21 出版日期:2021-08-21 发布日期:2021-07-29
基金资助:
北京肝胆相照公益基金会人工肝专项基金(RGGJJ-2021-005)。

Influencing factors of heparin anticoagulant effect in the treatment of double plasma molecular adsorption system

Kong Ming¹, Li Shuang², Geng Hua^1,3, Zhou Li¹, Xu Manman¹, Liu Jing², Chen Yu^1*

1. Fourth Department of Liver Disease, Beijing You'an Hospital, Capital Medical University, Beijing 100069, China;
2. Blood Purification Center, Beijing You'an Hospital, Capital Medical University, Beijing 100069, China;
3. Department of Infectious Diseases, Central Petroleum Hospital, Langfang 065000, Hebei Province, China

Received:2021-05-21 Online:2021-08-21 Published:2021-07-29
Contact: * E-mail:chybeyond1071@ccmu.edu.cn
Supported by:
Special Fund For Artificial Liver (RGGJJ-2021-005).

摘要/Abstract

摘要： 目的观察经验性肝素抗凝方案在双重血浆分子吸附系统(double plasma molecular adsorption system, DPMAS)治疗过程中的抗凝效果与安全性,分析影响抗凝效果的因素。方法选取2018年4月至2020年12月在首都医科大学附属北京佑安医院行DPMAS治疗的肝病患者102例,共进行治疗198次。根据DPMAS治疗过程中肝素抗凝效果分为抗凝良好组、抗凝不足组及抗凝过量组。比较不同的给药剂量组肝素抗凝效果良好例次的比例,比较3组患者基线临床资料的差异。结果 198例次均顺利完成治疗,其中抗凝良好组共118例次,抗凝不足组共11例次,抗凝过量组共69例次。当凝血酶原活动度(prothrombin activity, PTA)>30%、血小板计数(platelet, PLT)≤325×10⁹/L时,肝素抗凝效果良好例次的比例均＞70%;抗凝不良组患者体质量、血红蛋白(hemoglobin, Hb)、PLT显著高于抗凝良好组,差异有统计学意义(P<0.05);与抗凝良好组相比,抗凝过量组患者PTA、抗凝血酶活性(antithrombin activity, AT)、Hb降低,PT、APTT升高,差异有统计学意义(P<0.05);198例次治疗后24 h内,9例次患者出现中心静脉置管处渗血,1例次患者出现鼻腔出血,均未发生消化道出血等其他严重出血并发症;肝素过量组患者在治疗结束后24 h 活化部分凝血活酶时间(activated partial thromboplastin time, APTT)为(54.52±19.71) s,与治疗前比较,差异无统计学意义(P＞0.05)。结论当患者PTA>30%、PLT≤325×10⁹/L时,DPMAS治疗中依据治疗前24 h内PTA和PLT给予不同肝素剂量是可行的,但应考虑体质量、血红蛋白对抗凝效果的影响。

关键词: 肝, 人工, 双重血浆分子吸附系统, 肝素, 抗凝剂

Abstract: Objective To observe the anticoagulant effect and safety of empirical heparin anticoagulant regimen in the treatment of double plasma molecular adsorption system (DPMAS), and analyze the factors influencing the anticoagulant effect. Methods A total of 102 patients with liver disease treated by DPMAS in our hospital from April 2018 to December 2020 were selected, 198 times in total. According to the anticoagulation effect of heparin in the course of DPMAS treatment, they were divided into good anticoagulation group, insufficient anticoagulation group and excessive anticoagulation group. The proportion of cases with good anticoagulation effect in different dosage groups were compared, and the differences of baseline clinical data among the three groups were compared. Results There were 118 cases in good anticoagulation group, 11 cases in insufficient anticoagulation group and 69 cases in excessive anticoagulation group.When prothrombin activity (PTA)>30% and platelet (PLT)≤325×10⁹/L, the anticoagulant effect of heparin was good, and the proportion of cases was more than 70%. The body weight, hemoglobin(Hb) and PLT levels of patients with poor anticoagulation were significantly higher than those of patients with good anticoagulation (P<0.05). Compared with the good anticoagulant group, the levels of PTA, antithrombin activity(AT) and Hb in the excessive anticoagulant group were significantly lower, while the levels of PT and activated partial thromboplastin time(APTT) were significantly higher (P<0.05). Within 24 hours after 198 times of treatment, 9 patients had bleeding at the central venous catheter, 1 patient had nasal bleeding, and no other serious bleeding complications such as gastrointestinal bleeding occurred.The APTT level of heparin overdose group was (54.52±19.71)s at 24 hours after treatment, which was not significantly different from that before treatment. Conclusion When PTA>30% and PLT≤325×10⁹/L, it is feasible to give different doses of heparin according to PTA and PLT levels within 24 hours before treatment, but the influence of body weight and hemoglobin on anticoagulant effect should be considered.

Key words: liver, artificial, double plasma adsorption system, heparin, anticoagulants

中图分类号:

R575

孔明, 李爽, 耿华, 周莉, 徐曼曼, 刘静, 陈煜. 双重血浆分子吸附系统治疗过程中肝素抗凝效果的影响因素研究[J]. 首都医科大学学报, 2021, 42(4): 647-652.

Kong Ming, Li Shuang, Geng Hua, Zhou Li, Xu Manman, Liu Jing, Chen Yu. Influencing factors of heparin anticoagulant effect in the treatment of double plasma molecular adsorption system[J]. Journal of Capital Medical University, 2021, 42(4): 647-652.

参考文献

[1] 中华医学会感染病学分会肝衰竭与人工肝学组. 非生物型人工肝治疗肝衰竭指南(2016年版) [J]. 中华临床感染病杂志, 2016, 9(2): 97-103.
[2] 李爽, 陈煜. 血浆紧缺情况下非生物型人工肝治疗新模式的探讨 [J]. 临床肝胆病杂志, 2017, 33(9): 1687-1692.
[3] 李荣华, 傅蕾, 黄燕, 等. 双重血浆分子吸附治疗肝衰竭的临床研究 [J]. 中国现代医学杂志, 2018, 28(1): 78-82.
[4] Yao J, Li S, Zhou L, et al. Therapeutic effect of double plasma molecular adsorption system and sequential half-dose plasma exchange in patients with HBV-related acute-on-chronic liver failure [J]. J Clin Apheres, 2019, 34(4): 392-398.
[5] Guo X, Wu F, Guo W, et al. Comparison of plasma exchange, double plasma molecular adsorption system, and their combination in treating acute-on-chronic liver failure [J]. J Int Med Res, 2020, 48(6): 1-10.
[6] 董珍艳, 赵丹凤, 苏伟逸, 等. 肝素用于血浆置换及分子吸附再循环系统治疗肝衰竭安全性的Meta分析 [J]. 中国实用护理杂志, 2018, 34(11): 874-880.
[7] Ernst T, Holzer H, Otto R, et al. Efficacy and safety of anticoagulation with heparin versus heparin plus epoprostenol in patients undergoing extracorporeal liver support with prometheus [J]. Artif Organs, 2010, 34(1): 84-88.
[8] 张红玉, 崔慧斐. 肝素药理作用和药物制剂的研究新进展 [J]. 中国药学杂志, 2019, 54(22): 1831-1839.
[9] 陈香美. 血液净化标准操作规程 [M]. 北京:人民军医出版社, 2020:153.
[10] 翟原苑, 马海平, 郑宏, 等. 肝素与抗凝监测的研究进展 [J]. 临床和实验医学杂志, 2018, 17(1): 111-113.
[11] 毛平. 凝血酶法测定血浆肝素含量及其临床应用 [J]. 中华医学检验杂志, 1995, 18(5): 295-298.
[12] O'Leary J G, Greenberg C S, Patton H M, et al. AGA clinical practice update: coagulation in cirrhosis [J]. Gastroenterology, 2019, 157(1): 34-43.
[13] Kujovich J L. Coagulopathy in liver disease: a balancing act [J]. Hematol Am Soc Hematol Educ Program, 2015, 2015(1): 243-249.
[14] Olson S T, Richard B, Izaguirre G, et al. Molecular mechanisms of antithrombin-heparin regulation of blood clotting proteinases. A paradigm for understanding proteinase regulation by serpin family protein proteinase inhibitors [J]. Biochimie, 2010, 92(11): 1587-1596.
[15] Gray E, Hogwood J, Mulloy B. The anticoagulant and antithrombotic mechanisms of heparin [J]. Handb Exp Pharmacol, 2012, 207: 43-61.
[16] De Candia E, De Cristofaro R, Landolfi R. Thrombin-induced platelet activation is inhibited by high- and low-molecular-weight heparin [J]. Circulation, 1999, 99(25): 3308-3314.
[17] Lovecchio F. Heparin-induced thrombocytopenia [J]. Clin Toxicol (Phila), 2014, 52(6): 579-583.
[18] 向群, 袁素娥, 钱云, 等. 两种抗凝技术实施血浆置换的疗效对比研究 [J]. 医学临床研究, 2016, 33(11): 2166-2168.
[19] 周芸. 无肝素人工肝血浆置换术治疗肝功能衰竭的临床观察及护理 [J]. 实用临床医药杂志, 2017, 21(8): 46-48.
[20] Bembea M M, Annich G, Rycus P, et al. Variability in anticoagulation management of patients on extracorporeal membrane oxygenation: an international survey [J]. Pediatr Crit Care Med, 2013, 14(2): e77-84.
[21] 滕媛, 李勇男, 楼松, 等. 抗Xa活性在普通肝素抗凝监测中应用的研究进展 [J]. 中国体外循环杂志, 2018, 16(4): 63-66.
[22] Gutierrez-Bernays D, Ostwald M, Anstey C, et al. Transition from heparin to citrate anticoagulation for continuous renal replacement therapy: safety, efficiency and cost [J]. Ther Apher Dial, 2016, 20(1): 53-59.
[23] 邹鹏飞, 屠明敏, 戴霞红, 等. 小剂量阿加曲班与低分子肝素在李氏人工肝治疗中抗凝疗效及安全性比较[J]. 中华临床感染病杂志,2019,12 (3): 201-205.
[24] 马元吉, 陈芳, 许艳,等. 局部枸橼酸抗凝在血浆吸附联合血浆置换治疗高危出血倾向肝衰竭患者中的应用[J]. 世界华人消化杂志, 2018, 26(3):165-173.

双重血浆分子吸附系统治疗过程中肝素抗凝效果的影响因素研究

Influencing factors of heparin anticoagulant effect in the treatment of double plasma molecular adsorption system

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张莹, 刘超楠, 时红林, 刘芳, 陈德喜, 时红波. P53凋亡刺激蛋白2介导酒精性肝病脂代谢相关基因的转录组学分析[J]. 首都医科大学学报, 2023, 44(1): 85-92.
[2]	冯颖, 时克, 王宪波. 肝硬化合并肠系膜上静脉栓塞患者2年预后预测模型的构建与验证[J]. 首都医科大学学报, 2023, 44(1): 107-114.
[3]	刘遥, 冯颖, 任婕, 王宪波. 新型冠状病毒肺炎患者肝功能异常的影响因素及其在不同药物治疗中的动态变化[J]. 首都医科大学学报, 2022, 43(3): 433-439.
[4]	程芮, 朱思莹, 刘思茂, 周艳华, 宗晔, 李鹏, 张澍田. 内镜下治疗食管胃底静脉曲张伴发上消化道肿物的经验[J]. 首都医科大学学报, 2022, 43(1): 22-27.
[5]	安松林, 马玲, 赵月, 李雁. 主要促进因子超家族成员MFSD2A对肝癌细胞增殖、凋亡和侵袭的影响[J]. 首都医科大学学报, 2021, 42(6): 1000-1006.
[6]	张冬雪, 文祯, 孙玉燕, 姜涛. 初诊2型糖尿病患者中肝脏胰岛素清除率与临床特点及胃肠激素相关性的初步分析[J]. 首都医科大学学报, 2021, 42(5): 822-828.
[7]	程姣姣, 阮祥燕, 杜娟, 金凤羽, 李扬璐, 谷牧青. 卵巢组织冻存移植安全性的研究进展[J]. 首都医科大学学报, 2021, 42(4): 505-510.
[8]	陈建宏, 林欣, 冯金秋, 丁鹏鹏, 王苗苗, 林琳, 刘红, 吴静. 肝细胞条件性Eva1a/Tmem166基因敲除小鼠的表型分析[J]. 首都医科大学学报, 2021, 42(4): 568-574.
[9]	孙熙木, 王华光, 赵昕, 吕少诚, 贺强, 刘丽宏. 肝移植患者术后巨细胞病毒感染的危险因素分析[J]. 首都医科大学学报, 2021, 42(4): 664-671.
[10]	张菊霞, 吴安石. 背驮式与经典非转流式肝移植围术期临床疗效的研究[J]. 首都医科大学学报, 2020, 41(6): 954-959.
[11]	吴艳花, 王培刚, 安静. 基因的力量,让神秘的病毒无处躲藏——2020年诺贝尔生理学或医学奖简介[J]. 首都医科大学学报, 2020, 41(6): 1010-1013.
[12]	单姗, 丛敏. 锲而不舍、力克肝疾——贾继东教授[J]. 首都医科大学学报, 2020, 41(5): 839-843.
[13]	吕志彬, 关春爽, 闫铄, 陈七一, 李晶晶, 张羽君, 陈步东, 谢汝明. 人工智能在CT预测新型冠状病毒肺炎转归中的价值[J]. 首都医科大学学报, 2020, 41(3): 340-344.
[14]	李雪, 石中月, 杨志明, 庞文博, 金木兰. 人工智能辅助分析在宫颈液基薄层细胞学检查中的应用价值[J]. 首都医科大学学报, 2020, 41(3): 360-363.
[15]	曹迪, 李先亮, 张荟, 贺强. 影响肝门部胆管癌术后远期预后的因素[J]. 首都医科大学学报, 2020, 41(3): 439-443.